Claims for Patent: 10,323,075

Summary for Patent: 10,323,075

Title:	Compositions and methods of use for treating metabolic disorders
Abstract:	Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
Inventor(s):	Matern; Hugo (San Mateo, CA), Lindhout; Darrin Anthony (Mountain View, CA), Haldankar; Raj (Redwood City, CA), Horner; Geoffrey (San Francisco, CA)
Assignee:	NGM Biopharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	15/789,679
Patent Claims:	1. A dimer comprising two polypeptides, each of the two polypeptides comprising the amino acid sequence of SEQ ID NO: 32. 2. The dimer of claim 1, wherein at least one of the two polypeptides comprises an albumin fusion, wherein an albumin, an albumin variant, or an albumin fragment is conjugated to at least one of the two polypeptides. 3. The dimer of claim 2, wherein the albumin, albumin variant, or albumin fragment is human serum albumin, a human serum albumin variant, ora human serum albumin fragment, respectively, or bovine serum albumin, a bovine serum albumin variant, or a bovine serum albumin fragment, respectively, or cyno serum albumin, a cyno serum albumin variant, or a cyno serum albumin fragment, respectively. 4. The dimer of claim 2, wherein the albumin, albumin variant, or albumin fragment is conjugated to at least one of the two polypeptides at the carboxyl terminus or the amino terminus. 5. The dimer of claim 4, wherein the albumin, albumin variant, or albumin fragment is conjugated to at least one of the two polypeptides at the amino terminus. 6. The dimer of claim 4, wherein the albumin, albumin variant, or albumin fragment is conjugated to at least one of the two polypeptides via a linker. 7. The dimer of claim 6, wherein the linker is a cleavable linker. 8. The dimer of claim 7, wherein the cleavable linker can be cleaved by a protease. 9. The dimer of claim 6, wherein the linker is a non-cleavable linker. 10. The dimer of claim 1, wherein the dimer is N-glycosylated. 11. A genetically modified mammalian host cell that expresses the dimer of claim 1. 12. A pharmaceutical composition, comprising the dimer of claim 1, and a pharmaceutically acceptable diluent, carrier or excipient. 13. A pharmaceutical composition, comprising the dimer of claim 10, and a pharmaceutically acceptable diluent, carrier or excipient. 14. A sterile container comprising the pharmaceutical composition of claim 13. 15. The sterile container of claim 14, wherein the sterile container is a syringe. 16. A kit comprising the sterile container of claim 14. 17. A method of treating obesity in a mammalian subject, the method comprising administering to the subject the dimer of claim 1, wherein the dimer is administered in an amount effective to treat obesity in the subject. 18. The method of claim 17, wherein the administering is by parenteral injection. 19. The method of claim 18, wherein the parenteral injection is subcutaneous. 20. A method of treating hyperglycemia in a mammalian subject, the method comprising administering to the subject the dimer of claim 1, wherein the dimer is administered in an amount effective to treat the hyperglycemia in the subject. 21. The method of claim 20, wherein the subject has diabetes mellitus. 22. The method of claim 20, wherein the subject is human. 23. The method of claim 20, wherein the subject is obese. 24. The method of claim 20, wherein the administering is by parenteral injection. 25. The method of claim 24, wherein the parenteral injection is subcutaneous. 26. A method of treating obesity in a mammalian subject, the method comprising administering to the subject the dimer of claim 10, wherein the dimer is administered in an amount effective to treat obesity in the subject. 27. The method of claim 26, wherein the administering is by parenteral injection. 28. The method of claim 27, wherein the parenteral injection is subcutaneous. 29. A method of treating hyperglycemia in a mammalian subject, the method comprising administering to the subject the dimer of claim 10, wherein the dimer is administered in an amount effective to treat the hyperglycemia in the subject. 30. The method of claim 29, wherein the subject has diabetes mellitus. 31. The method of claim 29, wherein the subject is human. 32. The method of claim 29, wherein the subject is obese. 33. The method of claim 29, wherein the administering is by parenteral injection. 34. The method of claim 33, wherein the parenteral injection is subcutaneous.

Details for Patent 10,323,075

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2033-01-30
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2033-01-30
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2033-01-30
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2033-01-30